1. Home
  2. PHGE vs FRSX Comparison

PHGE vs FRSX Comparison

Compare PHGE & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • FRSX
  • Stock Information
  • Founded
  • PHGE 2015
  • FRSX N/A
  • Country
  • PHGE Israel
  • FRSX Israel
  • Employees
  • PHGE N/A
  • FRSX N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • FRSX Computer Software: Prepackaged Software
  • Sector
  • PHGE Health Care
  • FRSX Technology
  • Exchange
  • PHGE Nasdaq
  • FRSX Nasdaq
  • Market Cap
  • PHGE 13.3M
  • FRSX 13.7M
  • IPO Year
  • PHGE N/A
  • FRSX 2017
  • Fundamental
  • Price
  • PHGE $0.63
  • FRSX $0.69
  • Analyst Decision
  • PHGE Strong Buy
  • FRSX
  • Analyst Count
  • PHGE 2
  • FRSX 0
  • Target Price
  • PHGE $23.00
  • FRSX N/A
  • AVG Volume (30 Days)
  • PHGE 117.4K
  • FRSX 192.7K
  • Earning Date
  • PHGE 05-19-2025
  • FRSX 05-27-2025
  • Dividend Yield
  • PHGE N/A
  • FRSX N/A
  • EPS Growth
  • PHGE N/A
  • FRSX N/A
  • EPS
  • PHGE N/A
  • FRSX N/A
  • Revenue
  • PHGE N/A
  • FRSX $436,000.00
  • Revenue This Year
  • PHGE N/A
  • FRSX N/A
  • Revenue Next Year
  • PHGE N/A
  • FRSX N/A
  • P/E Ratio
  • PHGE N/A
  • FRSX N/A
  • Revenue Growth
  • PHGE N/A
  • FRSX N/A
  • 52 Week Low
  • PHGE $0.48
  • FRSX $0.57
  • 52 Week High
  • PHGE $4.99
  • FRSX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 49.87
  • FRSX 41.97
  • Support Level
  • PHGE $0.48
  • FRSX $0.61
  • Resistance Level
  • PHGE $0.58
  • FRSX $0.72
  • Average True Range (ATR)
  • PHGE 0.06
  • FRSX 0.04
  • MACD
  • PHGE 0.00
  • FRSX 0.01
  • Stochastic Oscillator
  • PHGE 68.16
  • FRSX 47.00

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its advanced systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

Share on Social Networks: